Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald Sells 12,128 Shares of Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald sold 12,128 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $452.18, for a total value of $5,484,039.04. Following the completion of the sale, the executive vice president owned 21,264 shares in the company, valued at approximately $9,615,155.52. This represents a 36.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Kevin Joseph Fitzgerald also recently made the following trade(s):

• On Thursday, October 2nd, Kevin Joseph Fitzgerald sold 2,441 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $452.05, for a total value of $1,103,454.05.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock opened at $445.79 on Friday. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The business has a 50 day simple moving average of $457.89 and a two-hundred day simple moving average of $388.61. The stock has a market capitalization of $58.90 billion, a P/E ratio of -180.48 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $495.55.

Institutional Trading of Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in ALNY. Root Financial Partners LLC bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at about $25,000. SVB Wealth LLC acquired a new stake in Alnylam Pharmaceuticals during the 1st quarter worth about $27,000. Salomon & Ludwin LLC purchased a new position in Alnylam Pharmaceuticals during the third quarter valued at approximately $27,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $29,000. Finally, Atlantic Union Bankshares Corp acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter worth about $30,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on ALNY shares. Canaccord Genuity Group lifted their price target on shares of Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Bank of America increased their price target on shares of Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the stock a “buy” rating in a research note on Wednesday, September 17th. Wall Street Zen raised Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday, November 10th. Evercore ISI lifted their price objective on Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an “outperform” rating in a report on Thursday, September 11th. Finally, Jefferies Financial Group cut their target price on shares of Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating for the company in a research note on Thursday, October 30th. Twenty-three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $482.17.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.